No representation is made as to the safety or effectiveness of 4D-150, 4D-710, 4D-310, 4D-125, or 4D-110 for the therapeutic uses for which they are being studied.ĤD Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. In addition, 4D Molecular Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting. The 4D preclinical product candidates in development are: 4D-175 for geographic atrophy and 4D-725 for AATLD.ĤD-150, 4D-710, 4D-310, 4D-125, and 4D-110 are our product candidates in clinical development and have not yet been approved for marketing by the US FDA or any other regulatory authority. 4DMT is currently advancing five product candidates in clinical development: 4D-150 for wet AMD and DME, 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease cardiomyopathy, 4D-125 for XLRP, and 4D-110 for choroideremia. Name, 4d Molecular Therapeutics Industry, Biotech Headquarters, Emeryville, California, Usa Company Type, Private Company Contact Number, (510) 505-2680. The 4DMT customized and evolved vectors were invented with the goal of being delivered at relatively low doses through clinically routine, well-tolerated, and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. ![]() The Company is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases: ophthalmology, pulmonology, and cardiology. All of our vectors are proprietary to 4DMT and were invented at 4DMT, including the vectors utilized in our clinical-stage and preclinical pipeline product candidates: R100, A101, and C102. 4DMT seeks to unlock the full potential of genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution, which combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our product candidates. ĤDMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases. Login or create a forever free account to read this news. REPORTS 6.7 PASSIVE STAKE IN 4D MOLECULAR THERAPEUTICS, INC. This brings 4DMT's total funding to $175M to date.Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at. 4D Molecular Therapeutics Inc FDMT: RA CAPITAL MANAGEMENT, L.P. The company raised $75M in Series C round on June 16, 2020. The company is headquartered in Emeryville, California.ĤDMT’s proprietary Therapeutic Vector Evolution platform enables a “disease first” approach to product discovery and development, thereby empowering customization of AAV vectors to target specific tissue types associated with the underlying disease.ĤDMT vectors are designed to exhibit improved therapeutic profiles that enable the company to pursue previously untreatable patient populations and to address a broad range of rare and large market disease markets.ĤDMT is backed Arrowmark Partners, Pfizer Ventures, Berkeley Catalyst Fund, Viking Global Investors, Amzak Health, Casdin Capital, Cystic Fibrosis Foundation, Longevity Vision Fund, MiraeAsset Financial Group and others. 4DMT is a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution.ĤDMT is harnessing the power of directed evolution to unlock the full potential of gene therapy for rare and large market diseases in lysosomal storage diseases, ophthalmology, neuromuscular diseases, and cystic fibrosis.ĤDMT was founded in 2013 by David Kirn, David Schaffer, Theresa Janke and Melissa Kotterman. 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |